This hypothesis is supported by the observation that RANKL induces the migration of various RANK-expressing cancer cell lines in vitro, in a manner that is blocked by RANKL inhibitors (OPG or sRANK/RANK-Fc). Here, TNFRSF11A is linked to cancer.